

Original Article

Role of platelet-rich plasma in chronic alopecia areata: Our centre experience

Sukhbir Singh

Department of Burns, Plastic and Aesthetic Surgery, Kamal Hospital, Kaushambi, Uttar Pradesh, India

Address for correspondence: Dr. Sukhbir Singh, S-212, Greater Kailash Part 2, New Delhi - 110 048, India. E-mail: sukhi_1@yahoo.com

ABSTRACT

Aim: The aim of the study was to evaluate the efficacy of platelet-rich plasma (PRP) in the treatment of chronic alopecia areata (AA). **Material and Methods:** This is a prospective study that was conducted at Kamal Hospital, Kaushambi in which 20 patients who attended the outpatient department were enrolled for the study. All the patients had h/o patches and taken various line of treatments for a duration of 2 years. All the patients were biopsy-proven positive for AA disease. There was no randomisation done since all of them were healthy young adults. The patients' age ranged from 25 to 35 years, and none of them had any co-morbidities. **Results:** Of 20 patients, only one patient had a relapse. None of the patients had any side effects, and all of them tolerated the procedure well. **Conclusion:** We wish to conclude that PRP has a definite role in treating AA infections. However, still more long-term follow-up, studies are required for further validation of results and labelling it as a 100% cure for people suffering from AA with recurrences which are so common.

KEY WORDS

Alopecia areata; platelet rich plasma; cicatricial alopecia

INTRODUCTION

Alopecia areata (AA) is a common, non-scarring, autoimmune disease that can affect any hair-bearing area. Though various lines of management have been described for this condition,^[1-5] all have significant relapse rate with, with side effects of the medications too. In this paper, we discuss 20 patients of chronic, biopsy proved AA disease, who had taken (unsuccessfully) 2 years of various forms of therapy.

Platelet-rich plasma (PRP) is a preparation of autologous platelets in concentrated plasma. It has been investigated in several disciplines of medicine for its role in wound healing. In our centre, we have treated 20 patients of alopecia areata with PRP alone, without any side effects, and with good preliminary results as seen in Figure 1a and b.

We decided to use PRP for improvement of the patient's outcome as we had success in the use of PRP for hair rejuvenation and cicatricial alopecia.^[6,7] There has been only one double-blinded, placebo and active-controlled, half-head, parallel group study on 45 patients to evaluate the efficacy and safety of PRP in AA patients.^[8] This study concluded that PRP is a safe and alternative treatment for AA, but further controlled trials are needed to validate the findings.

Access this article online	
Quick Response Code: 	Website: www.ijps.org
	DOI: 10.4103/0970-0358.155271




Figure 1: (a) Pre-intervention state of the patient with alopecia areata (b) post-platelet rich plasma status-note the improved sustained hair growth at the end of 1 year

MATERIAL AND METHODS

This is a prospective study that was conducted at Kamal Hospital, Kaushambi in which 20 patients who attended the outpatient department were enrolled for the study. All the patients had h/o patches and taken various lines of treatments for a duration of 2 years. All the patients were biopsy-proven positive for AA disease. There was no particular randomisation done since all of them were healthy young adults. The patients' ages ranged from 25 to 35 years, and none had any co-morbidities. All the patients were explained about the procedure in detail. A consent form was signed by each patient. All the patients were followed up at 4 weekly intervals for a duration of 6 months and then at the end of 1 year. All the patients received 6 sessions of PRP. Ethics committee approval was taken prior to the commencement of the study.

Treatment protocol

A volume of 25 ml blood was taken from each patient and the PRP solution obtained from the lab was used within 30 min of its preparation. It was injected in the scalp after local anaesthesia application, in the subfollicular plane. Patients were sent home once the PRP session was over, and they were in a stable condition which was confirmed after checking all the vitals. They were called for review after 4 weeks for the next session and told to report earlier if any need arose. All the patients received 6 sessions of PRP at 4 weekly intervals. Patients were reviewed every month for 6 months and then at the end of 1 year.

RESULTS

Of the 20 patients, one patient had a relapse, and his hair regrowth was also minimum [Figure 2a-c]. None of the patients had any side effects, and all of them tolerated the procedure well.




Figure 2: (a) Pre-intervention state of the patient with alopecia areata (b) post-platelet rich plasma (PRP) status-note the improved hair growth at the end of 6 months (c) post-PRP status-note the relapse at the end of 1 year

DISCUSSION

Proper counselling of the patient is very important before starting treatment for this disease since it is associated with recurrences very commonly. All the treatments available as of today are associated with both relapses and side effects, which affects the psychosocial life of the patients in the long run.

Various treatments are available for AA affliction. The effect of a single intralesional corticosteroid injection has been observed to persist for up to 9 months. In a few studies,^[2] reported relapse rates were 29% in limited AA and 72% in alopecia totalis during a 3-month follow-up period.^[1] The reported relapse rate of topical steroids is 37-63%.^[4,5] In a placebo-controlled, double-blind study, hair regrowth was observed in 63.6% and 35.7% of the minoxidil-treated and placebo groups, respectively.^[9] In another study, hair regrowth was achieved in 38% and 81% of patients treated with 1% and 5% topical minoxidil, respectively.^[10] Side effects include contact dermatitis and facial hypertrichosis. Various forms of systemic corticosteroids have been used in different regimens. In one study, a once-monthly oral pulse of 300 mg prednisone induced a complete response in 41% of patients.^[11] A similar effect has been reported in a placebo-controlled trial of oral prednisolone 200 mg once weekly in the treatment of extensive AA.^[12] The relapse rate was 25%, and side effects of the therapy were noted in 55% of patients.^[12] Other medications include methotrexate (with relapse rate of more than 50%); cyclosporine (with a high relapse rate of almost 100%);^[13] azathioprine, and others.

There has been only one double-blinded, placebo and active-controlled, half-head, parallel group study on 45 patients to evaluate the efficacy and safety of PRP in AA patients,^[8] which concluded that PRP is a safe and alternative treatment for AA, but further controlled trials are needed to validate the findings. Our study showed relapse in just one case and no side effects in any of the 20 treated patients. Though we have achieved initial success with PRP, further follow-up is required, and more studies needed to validate the final results.

REFERENCES

1. Abell E, Munro DD. Intralesional treatment of alopecia areata with triamcinolone acetonide by jet injector. *Br J Dermatol* 1973;88:55-9.
2. Orentreich N, Sturm HM, Weidman AI, Pelzig A. Local injection of steroids and hair regrowth in alopecias. *Arch Dermatol* 1960;82:894-902.
3. Mancuso G, Balducci A, Casadio C, Farina P, Staffa M, Valenti L, *et al.* Efficacy of betamethasone valerate foam formulation in comparison with betamethasone dipropionate lotion in the treatment of mild-to-moderate alopecia areata: A multicenter, prospective, randomized, controlled, investigator-blinded trial. *Int J Dermatol* 2003;42:572-5.
4. Tosti A, Piraccini BM, Pazzaglia M, Vincenzi C. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. *J Am Acad Dermatol* 2003;49:96-8.
5. Pascher F, Kurtin S, Andrade R. Assay of 0.2 percent fluocinolone acetonide cream for alopecia areata and totalis. Efficacy and side effects including histologic study of the ensuing localized acneiform response. *Dermatologica* 1970;141:193-202.
6. Singh S. Platelet rich plasma — Protocol for its preparation and its role in hair rejuvenation. *Aestheticians J* 2013;3:40-2.
7. Singh S. Role of platelet rich plasma in primary cicatricial alopecia. *Aestheticians J* 2014;4:42-4.
8. Trink A, Sorbellini E, Bezzola P, Rodella L, Rezzani R, Ramot Y, *et al.* A randomized, double-blind, placebo-and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata. *Br J Dermatol* 2013;169:690-4.
9. Price VH. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. *J Am Acad Dermatol* 1987;16:730-6.
10. Fiedler-Weiss VC. Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata. *J Am Acad Dermatol* 1987;16:745-8.
11. Ait Ourhroui M, Hassam B, Khoudri I. Treatment of alopecia areata with prednisone in a once-monthly oral pulse. *Ann Dermatol Venereol* 2010;137:514-8.
12. Kar BR, Handa S, Dogra S, Kumar B. Placebo-controlled oral pulse prednisolone therapy in alopecia areata. *J Am Acad Dermatol* 2005;52:287-90.
13. Gupta AK, Ellis CN, Cooper KD, Nickoloff BJ, Ho VC, Chan LS, *et al.* Oral cyclosporine for the treatment of alopecia areata. A clinical and immunohistochemical analysis. *J Am Acad Dermatol* 1990;22:242-50.

How to cite this article: Singh S. Role of platelet-rich plasma in chronic alopecia areata: Our centre experience. *Indian J Plast Surg* 2015;48:57-9.

Source of Support: Nil, **Conflict of Interest:** None declared.

New features on the journal's website

Optimized content for mobile and hand-held devices

HTML pages have been optimized of mobile and other hand-held devices (such as iPad, Kindle, iPod) for faster browsing speed.

Click on **[Mobile Full text]** from Table of Contents page.

This is simple HTML version for faster download on mobiles (if viewed on desktop, it will be automatically redirected to full HTML version)

E-Pub for hand-held devices

EPUB is an open e-book standard recommended by The International Digital Publishing Forum which is designed for reflowable content i.e. the text display can be optimized for a particular display device.


Click on **[EPub]** from Table of Contents page.

There are various e-Pub readers such as for Windows: Digital Editions, OS X: Calibre/Bookworm, iPhone/iPod Touch/iPad: Stanza, and Linux: Calibre/Bookworm.

E-Book for desktop

One can also see the entire issue as printed here in a 'flip book' version on desktops.

Links are available from Current Issue as well as Archives pages.

Click on  View as eBook